Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis

BMC Pulmonary Medicine

Table 1 Patient characteristics at baseline by survival status

Characteristic	Survivors (n = 26)	Non-survivors (n = 20)	p-value
Description
Age, years	65.8 (6.8)	69.2 (8.5)	0.14
Male	18 (69%)	17 (85%)	0.21
BMI, kg/m²	28.2 (4.0)	27.7 (4.9)	0.67
Use of Antifibrotic Therapy	24 (92%)	14 (70%)	0.048
LTOT	5 (20%)	5 (25%)	0.69
pO₂ at rest, mmHg	72.1 (8.2)	70.2 (9.7)	0.50
Lung Function
FVC, liter	3.1 (0.8)	2.3 (0.7)	0.002
FVC, %pred.	85.1 (21.4)	64.3 (17.2)	0.001
FEV₁ / FVC	0.85 (0.06)	0.81 (0.07)	0.08
DLCO, %pred.	48.7 (13.5)	35.9 (12.9)	0.002
Exercise Capacity
6MWD, meters	415 (128)	299 (118)	0.003
Physical Activity
Steps per day	6606 (3064)	3433 (2655)	+0.001
Disease Severity
GAP Score	4 [2–4]	5 [4–5]	0.005
GAP Stage	II [I – II]	II [II – II]	0.02
Comorbidities
Pulmonary Hypertension	1 (4%)	1 (5%)	0.85
Arterial Hypertension	9 (35%)	10 (50%)	0.29
Cardiovascular Diseases^a	7 (27%)	7 (35%)	0.56
Diabetes Mellitus	1 (4%)	4 (20%)	0.08
GERD	6 (23%)	2 (10%)	0.25
Lung Cancer	0	1 (4%)	0.25
Depression	1 (4%)	0	0.38
Mean number of comorbidities per patient ≥ 1^b	17 (65%)	17 (85%)	0.13

Data are presented as mean (SD), median [IQR] or n (%) depending on scale and distributional characteristics
Data were missing for LTOT (n = 1) and pO2 (n = 2)
Abbreviations: LTOT long-term oxygen therapy, pO ₂ partial pressure of oxygen in capillary blood analysis, FVC forced vital capacity, FEV ₁ forced expiratory volume at one second, DLCO diffusing capacity of the lung for carbon monoxide, 6MWD 6-min walking-distance, GAP Gender-Age-Physiology, GERD gastro-esophageal reflux disease
^aCardiovascular diseases encompassed coronary artery disease, left heart failure or any other cardiovascular diseases, respectively
^b N = 9 (35%) and n = 3 (15%) patients had no comorbidities, respectively. Nobody had ≥4 comorbidities

ISSN: 1471-2466